Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

145.25 -1.55 (-1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 825,986
Open 146.70
Bid (Size) 145.12 (12)
Ask (Size) 145.21 (2)
Prev. Close 146.80
Today's Range 144.25 - 147.60
52wk Range 99.98 - 150.39
Shares Outstanding 100,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:NBIX, a growth stock which is not overvalued.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill

Performance

YTD
+10.26%
+10.26%
1 Month
+3.67%
+3.67%
3 Month
+4.58%
+4.58%
6 Month
+2.13%
+2.13%
1 Year
+42.56%
+42.56%

More News

Read More
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors.
Via Chartmill
Key Takeaways From Neurocrine Biosciences Analyst Ratings
Via Benzinga
Exploring NASDAQ:NBIX's quality characteristics.
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Via Chartmill
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
Via Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
In the world of growth stocks, NASDAQ:NBIX shines as a value proposition.
Via Chartmill
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
Via Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Via Investor's Business Daily
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Via Investor's Business Daily
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Via Chartmill
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.